Untreated, the outlook is poor: half of all men suffering from familial hypercholesterolaemia may expect to die from coronary heart disease by the age of 60.2 In the rare homozygous form symptoms of coronary heart disease may occur in childhood.
The condition results from a genetic deficiency of specific cell surface receptors normally responsible for removing cholesterol rich low density lipoprotein, and blood lipid analysis will usually show a substantially raised concentration of total cholesterol as a result of increased levels of low density lipoprotein cholesterol (in adults usually greater than 5 mmol/l) with other lipid and lipoprotein concentrations relatively normal.3 Familial hypercholesterolaemia may be diagnosed from cord blood at birth. On the basis of the number of known homozygotes, Slack has estimated a frequency of one in 500 in Britain, but in some other countries (for example, South Africans of Dutch origin) rates are believed to be substantially. higher. 4 In view of the fairly high frequency, the ominous prognosis in untreated sufferers, and the relative ease of diagnosis it is surprising that the condition has not aroused greater interest. This probably results from a failure by clinicians to appreciate how common the condition is and the lack of evidence that treatment improves the outlook. Effective lowering of cholesterol by dietary modification and drug treatment can certainly reduce the size of the xanthomas. Recently the Lipid Research Clinics' much publicised trial of patients treated with cholestyramine (which included some with familial hypercholesterolaemia) has confirmed the circumstantial evidence suggesting that adequate lowering of cholesterol can produce an appreciable reduction in morbidity and mortality from cardiovascular disease.56 As a result of the trial cholestyramine is widely regarded as the drug of choice in patients resistant to dietary treatment (most of those with familial hypercholesterolaemia), but probucol, nicotinic acid, and bezafibrate have been used in the few patients not able to tolerate cholestyramine. These drugs have also been used in conjunction with cholestyramine when it alone has not produced adequate lowering of cholesterol. Ileal bypass surgery has been used with some success in a few specialist centres in patients resistant to drug treatment. Management of the rare homozygous form presents special problems reviewed in detail elsewhere.7 Against this background patients with familial hypercholesterolaemia have formed a new self help organisation-the Familial Hypercholesterolaemia Association-which aims to make the public and medical profession more aware of the condition, to inform and support those found to have familial hypercholesterolaemia, and to encourage further research into the cause and treatment of the condition. Its address is PO Box 612, London W2 2EE.
Medical education and manpower in the European Economic Community
Without having anything quite like a common medical policy the European Economic Community has achieved a doctor mountain. What to do with it is a headache for all of those concerned, and that must potentially include Britain. We can scarcely plough doctors back into the ground or sell them cheap to the Russians. Nobody doubts that they could be helpful in the world, given the right opportunities for their use. So could butter and eggs and milk and, some might say, even wine. Cutting down their production will not make doctors go away; their very imperishability, as well as their social and economic value, intensifies the embarrassment of their overproduction.
While we are trying to decide whether Britain is itself training too many doctors (and our problem, if it exists at all,
